Kwality Pharmaceuticals share news and announcements
NSE: KPLBSE: 539997Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹3,618.30.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹3,661 Cr1,235th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 10 Aug 2026
- 45.2
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 19 May 2026
- 11.0
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 10 Aug 2026
- 27.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 10 Aug 2026
- 25.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 19 May 2026
- 0.40
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 38,71643.8% delivered
Kwality Pharmaceuticals share news and announcements
373 announcements, routine notices left out, newest first. Page 4 of 8.
Apr 2023
30 Apr · Certificate Under Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) For The Year Ended On 31St March, 2023
24 Apr · Announcement Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements), Regulations, 2015 - Kwality Pharmaceuticals Himachal Pradesh Facility Received EU GMP Approval
11 Apr · Compliance Certificate - Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015. For March 31, 2023
Mar 2023
30 Mar · Announcement Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements), Regulations, 2015 - Kwality Pharmaceuticals Received ANVISA Approval For Cephalosporin Plant (Unit -II)
Feb 2023
7 Feb · Board meeting
Meeting on 14 Feb 2023: quarterly results
Jan 2023
Dec 2022
27 Dec · Announcement Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements), Regulations, 2015 - EU GMP INSPECTION ACCEPTENACE RECEIVED FROM BULGARIA FOR EU (European Union) AUDIT
21 Dec · Announcement Under Regulation 30 Of SEBI {Listing Obligations And Disclosure Requirements). Regulations. 2015 - KWALITY PHARMA GOT BRAZIL's ANVISA APPROVAL OF GENERIC INJECTABLE ALONG WITH ONCOLOGY INJECTABLE UNIT. H.P.
15 Dec · Announcement Under Regulation 30 Of SEBI Listing Qbligations And Disclosure Requirements). Regulations. 2015 - Kwality Pharmaceuticals Received ANVISA Approval For Oncology Injection
Nov 2022
29 Nov · Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 (Listing Regulations') For The Half Year Ended September 30, 2022
7 Nov · Board meeting
Meeting on 14 Nov 2022: quarterly results
Oct 2022
18 Oct · Statement Of Investor Complaints For The Quarter Ended September 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Sep 2022
7 Sep · Reg. 34 (1) Annual Report.
6 Sep · Legal
Exchange has sought clarification from Kwality Pharmaceuticals Ltd on September 5, 2022 with reference to significant movement in price, in order to ensure that investors have latest ....
Aug 2022
4 Aug · Board meeting
Meeting on 13 Aug 2022: quarterly results
Jul 2022
12 Jul · Statement Of Investor Complaints For The Quarter Ended June 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Jun 2022
24 Jun · Disclosure For Intimation Received From Mr. Sachin Seth (Member Of Promoter Group) For Disposal Of Equity Shares Of Kwality Pharmaceuticals Limited.